Building a leading lymphoma portfolio by evolving our research for patients with indolent NHL
Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) are 2 types in a class of slow-growing B-cell cancers referred to as indolent non-Hodgkin’s Lymphomas (iNHLs). These incurable lymphomas are primarily slow-growing, exhibit extremely variable outcomes and are characterized by immune dysfunction within the tumor microenvironment.
The iNHL therapeutic standard of care is immunochemotherapy consisting of traditional chemotherapy combined with an anti-CD20 monoclonal antibody. Despite initially achieving good responses, most patients with iNHL will relapse and will experience multiple relapses that require multiple rounds of therapeutic intervention. Durability of responses has been shown to diminish with each line of therapy.
Celgene is a pioneer in developing novel therapies for treatment of hematologic malignancies. Based on our improved understanding of iNHL disease biology, we are challenging the Chemotherapy-based standard of care by exploring chemotherapy-free options that seek to address the underlying immune dysfunction that drives and contributes to this class of diseases.
Advocacy & Collaboration
Learn about various relationships and collaborations that help drive innovation in iNHL:
Celgene remains committed to addressing the needs of patients with all types of lymphoma, including indolent NHL. By evolving our understanding of the mechanisms behind these malignancies, exploring alternative delivery pathways, and developing new molecules, we hope to improve the lives of patients living with these diseases.